An intervention program that coaches patients in stress management and goal setting, along with a digital app, helped ...

UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free ...

Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with ...

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $16.00 ...

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...

01 优时比和渤健公布了3期PHOENYCS GO研究的详细结果，显示dapirolizumab pegol与标准治疗联用显著改善中度至重度系统性红斑狼疮患者的疾病活动程度。 今日，优时比（UCB）和渤健（Biogen）公布了3期PHOENYCS ...

The 321-subject trial is comparing the anti-CD40L antibody to placebo on top of standard care in SLE patients, with the primary endpoint response on the BILAG 2004-based Composite Lupus Assessment ...

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that Chief Operating Officer Jessica Morris will present at the Winter 2024 Investor Summit Virtual ...

The two patients received the treatment as part of a UChicago Medicine pilot study focusing on the use of Eledon's anti CD40 ligand (CD40L) antibody tegoprubart (formerly AT-1501) as an ...

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Free Report) – Analysts at Cantor Fitzgerald raised their FY2024 EPS estimates ...